Eric MD - Lexeo Therapeutics, Chief Research
| LXEO Stock | 3.38 0.35 9.38% |
Executive
Eric MD is Chief Research of Lexeo Therapeutics, Common
| Age | 51 |
| Phone | 212 547 9879 |
| Web | https://www.lexeotx.com |
Lexeo Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.3993) % which means that it has lost $0.3993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7483) %, meaning that it created substantial loss on money invested by shareholders. Lexeo Therapeutics,'s management efficiency ratios could be used to measure how well Lexeo Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marc Weede | Aegon NV ADR | 58 | |
| Caroline Ramsay | Aegon NV ADR | 59 | |
| Addam Chupa | InfuSystems Holdings | 46 | |
| Bradley Dawson | Aegon NV ADR | N/A | |
| Jeremy Siegfried | Rocky Brands | N/A | |
| John Landry | Nyxoah | 52 | |
| Mark Ellman | Aegon NV ADR | 64 | |
| Dona Young | Aegon NV ADR | 66 | |
| Jerod Funke | InfuSystems Holdings | 50 | |
| Astrid Jakel | Aegon NV ADR | 48 | |
| Jack McGarry | Aegon NV ADR | 63 | |
| David DeMartino | Nyxoah | N/A | |
| Onno Klinken | Aegon NV ADR | 56 | |
| An Moonen | Nyxoah | N/A | |
| Jan Weidema | Aegon NV ADR | N/A | |
| Ben Noteboom | Aegon NV ADR | 62 | |
| Jane Daniel | Aegon NV ADR | N/A | |
| Ben Veer | Aegon NV ADR | 69 | |
| Carla Mahieu | Aegon NV ADR | 61 | |
| Maggie McGowan | Nyxoah | N/A | |
| Mikaela Kirkwood | Nyxoah | N/A | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.4 |
Lexeo Therapeutics, Leadership Team
Elected by the shareholders, the Lexeo Therapeutics,'s board of directors comprises two types of representatives: Lexeo Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lexeo. The board's role is to monitor Lexeo Therapeutics,'s management team and ensure that shareholders' interests are well served. Lexeo Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lexeo Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ryan McHenry, VP Controller | ||
| Nolan Townsend, CEO Director | ||
| Rand Monaghan, Vice Finance | ||
| Paul McCormac, Chief Officer | ||
| Jordan MD, Cardiology Science | ||
| Ronald MD, Chief CoFounder | ||
| Jenny Robertson, Chief Officer | ||
| Sandi MD, Senior Operations | ||
| PharmD Rasbach, Chief Officer | ||
| Jose Otero, Chief Officer | ||
| Eric MD, Chief Research | ||
| Jenny JD, Chief Officer | ||
| Micah Zajic, Chief Officer |
Lexeo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lexeo Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | (23.24 M) | ||||
| Shares Outstanding | 33.06 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 91.48 % | ||||
| Number Of Shares Shorted | 1.88 M | ||||
| Price To Book | 0.92 X | ||||
| EBITDA | (66.67 M) | ||||
| Net Income | (66.39 M) |
Pair Trading with Lexeo Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against Lexeo Stock
The ability to find closely correlated positions to Lexeo Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics, Common to buy it.
The correlation of Lexeo Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.